Covid-19 drug prevents symptomatic illness in study, Regeneron says
Antibody drug from Regeneron Pharmaceuticals Inc. reduced risk of developing symptoms Covid-19 81% compared to a placebo in people living with someone infected with the novel coronavirus, a study found.
The results indicate potential new preventive applications for the drug, which is already being used to treat previous cases of Covid-19.
Regeneron said on Monday it would ask the U.S. Food and Drug Administration to extend authorization for the drug to people exposed to the virus who have not yet been vaccinated, which could provide interim protection such as people are waiting for vaccines.
So far, 21.3% of the US population has been fully vaccinated and 35.3% has received at least one vaccine.
“As more than 60,000 Americans continue to be diagnosed with Covid-19 every day, the REGEN-COV antibody cocktail can help provide immediate protection to unvaccinated people who are exposed to the virus,” said George D Yancopoulos, President and Chief Scientific Officer of Regeneron. officer.